PTGX logo

Protagonist Therapeutics, Inc

PTGX

PTGX: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

more

Show PTGX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of PTGX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by PTGX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Conjugated hepcidin mimetics Sep. 12, 2023
  • Patent Title: Analogues of hepcidin mimetics with improved in vivo half lives Oct. 18, 2022
  • Patent Title: Α4α7 peptide monomer and dimer antagonists Sep. 07, 2021
  • Patent Title: Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Jun. 22, 2021
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Mar. 09, 2021
  • Patent Title: Opioid agonist peptides and uses thereof Aug. 04, 2020
  • Patent Title: Hepcidin analogues and uses thereof Dec. 10, 2019
  • Patent Title: Hepcidin analogues and uses thereof Oct. 15, 2019
  • Patent Title: Methods for synthesizing α4β7 peptide antagonists Sep. 10, 2019
  • Patent Title: Cyclic monomer and dimer peptides having integrin antagonist activity May. 28, 2019
  • Patent Title: Opioid agonist peptides and uses thereof May. 07, 2019
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Feb. 05, 2019
  • Patent Title: Α4β7 thioether peptide dimer antagonists Aug. 28, 2018
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 31, 2018
  • Patent Title: Hepcidin analogues and uses thereof Jul. 24, 2018
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 17, 2018
  • Patent Title: Hepcidin analogues and uses thereof Nov. 21, 2017
  • Patent Title: Α4β7 peptide monomer and dimer antagonists Nov. 07, 2017
  • Patent Title: A4b7 integrin thioether peptide antagonists Jul. 25, 2017
  • Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Apr. 18, 2017
  • Patent Title: Α4β7 peptide dimer antagonists Mar. 01, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of PTGX in WallStreetBets Daily Discussion

PTGX News

Recent insights relating to PTGX

CNBC Recommendations

Recent picks made for PTGX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PTGX

Corporate Flights

Flights by private jets registered to PTGX